GH Research PLC $GHRS Stock: Jefferies Financial Group Inc. Trims Stake

Jefferies Financial Group Inc. trimmed its position in shares of GH Research PLC (NASDAQ:GHRS) by 49.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 362,361 shares of the company’s stock after selling 349,939 shares during the quarter. Jefferies Financial Group Inc.’s holdings in GH Research were worth $8,508,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of GHRS. Troluce Capital Advisors LLC boosted its holdings in shares of GH Research by 165.4% in the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock valued at $13,926,000 after buying an additional 617,260 shares in the last quarter. Braidwell LP purchased a new position in shares of GH Research in the 2nd quarter worth approximately $5,571,000. Renaissance Technologies LLC bought a new position in shares of GH Research during the 1st quarter worth approximately $290,000. Squarepoint Ops LLC bought a new position in shares of GH Research during the 2nd quarter worth approximately $495,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of GH Research by 30.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,525 shares of the company’s stock worth $432,000 after acquiring an additional 4,106 shares in the last quarter. 56.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Wall Street Zen cut shares of GH Research from a “hold” rating to a “sell” rating in a research report on Saturday, October 24th. Needham & Company LLC lifted their price target on shares of GH Research from $32.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wells Fargo & Company began coverage on shares of GH Research in a report on Monday, July 27th. They issued an “overweight” rating and a $44.00 price target on the stock. Guggenheim upped their price target on GH Research from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a report on Thursday, October 15th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.00.

GH Research Stock Down 1.6%

GHRS stock opened at $19.25 on Thursday. The stock has a market capitalization of $1.32 billion, a PE ratio of -19.25 and a beta of 1.31. GH Research PLC has a 52 week low of $12.04 and a 52 week high of $31.44. The firm has a 50 day moving average of $22.67 and a 200 day moving average of $21.62.

GH Research Profile

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.